Hormone-refractory prostate cancer is common and only the combination of docetaxel and prednisone has been shown to improve survival. Targeted therapies have revolutionized the treatment of cancer. Advances in our understanding of the molecular mechanism underlying prostate cancer progression has translated into a variety of treatment approaches. However, the treatment of elderly patients with these new biological therapies remains a challenge and few data are available concerning the toxicity of biological drugs in the elderly population.
|Number of pages||9|
|Journal||Geriatric and Medical Intelligence|
|Publication status||Published - 2010|
ASJC Scopus subject areas
- Geriatrics and Gerontology